Opinion|Videos|July 16, 2026

Historic Treatments and the Need for Menin Inhibitors

Menin inhibitors offer new hope in relapsed KMT2A/MP1 AML, controlling disease to reach remission and allogeneic stem cell transplant.

In this episode, Sanja Zepcan, PharmD, BCPS, BCOP, explores the limitations of salvage chemotherapy regimens in this patient population and introduces allogeneic stem cell transplant as the only curative option. She discusses why menin inhibitors represent a paradigm shift as a bridge to transplant and shares why pharmacists must understand transplant eligibility as a meaningful treatment end point, not a distant contingency.

Latest CME